ARK Investment Management 大幅增持 Beam Therapeutics 股份

根據最近向美國證券交易委員會提交的 13F 表格，ARK Investment Management LLC 在第四季度將其持有的 Beam Therapeutics Inc.（NASDAQ：BEAM - 免費報告）股份增加了 6.9%。該公司在本季額外購買了 609,998 股後，擁有 9,393,889 股該公司股票。 Beam Therapeutics 約佔 ARK Investment Management LLC 投資組合的 1.5%，使其在該股中排名第 21 位。

ARK Investment Management Bolsters Stake in Beam Therapeutics

ARK Investment Management 增持 Beam Therapeutics 股份

ARK Investment Management LLC has significantly increased its position in shares of Beam Therapeutics Inc. (NASDAQ: BEAM), a biotechnology company focused on developing precision genetic medicines. According to the firm's latest Form 13F filing with the Securities and Exchange Commission, ARK purchased an additional 609,998 shares during the fourth quarter of 2022, representing a 6.9% increase in its holdings.

ARK Investment Management LLC 大幅增持了 Beam Therapeutics Inc.（納斯達克股票代碼：BEAM）的股份，Beam Therapeutics Inc. 是一家專注於開發精準基因藥物的生物技術公司。根據該公司向美國證券交易委員會提交的最新 13F 表格，ARK 在 2022 年第四季額外購買了 609,998 股股票，相當於其持股增加了 6.9%。

After the transaction, ARK owned 9,393,889 shares of Beam Therapeutics, constituting approximately 1.5% of its portfolio and making BEAM its 21st largest position. The firm's stake in the company was valued at $255,702,000 at the end of the quarter.

交易完成後，ARK 持有 Beam Therapeutics 的 9,393,889 股，約佔其投資組合的 1.5%，使 BEAM 成為其第 21 位持股最多的公司。截至本季末，該公司持有的該公司股份價值為 255,702,000 美元。

Strong Institutional Support for Beam Therapeutics

對光束治療的強有力的機構支持

Other hedge funds have also expressed confidence in Beam Therapeutics. Point72 Middle East FZE established a new position in the company during the fourth quarter, valued at approximately $35,000. Allworth Financial LP expanded its holdings by 163.7% during the third quarter, now owning 1,105 shares worth $27,000. Canada Pension Plan Investment Board and Penserra Capital Management LLC both purchased new stakes in the company during the first quarter, valued at approximately $86,000 and $97,000, respectively. Captrust Financial Advisors increased its position by 29.9% in the first quarter, owning 1,845 shares valued at $106,000.

其他對沖基金也表達了對 Beam Therapeutics 的信心。 Point72 Middle East FZE 在第四季度在公司設立了一個新職位，價值約為 35,000 美元。 Allworth Financial LP 第三季持股增加了 163.7%，目前持有 1,105 股，價值 27,000 美元。加拿大退休金計畫投資委員會和 Penserra Capital Management LLC 在第一季均購買了該公司的新股份，價值分別約為 86,000 美元和 97,000 美元。 Captrust Financial Advisors 在第一季持倉量增加了 29.9%，持有 1,845 股，價值 106,000 美元。

Institutional investors collectively hold a significant 99.68% of Beam Therapeutics' outstanding shares, reflecting the strong institutional support for the company.

機構投資人合計持有Beam Therapeutics 99.68%的流通股，反映出機構對公司的大力支持。

Insider Transactions

內線交易

Beam Therapeutics has also experienced some insider activity. Insider Christine Bellon sold 1,907 shares on January 3rd at an average price of $26.42 per share, totaling $50,382.94. Following the transaction, she directly owns 80,495 shares of the company's stock, valued at $2,126,677.90.

Beam Therapeutics 也經歷了一些內幕活動。內部人士 Christine Bellon 於 1 月 3 日出售了 1,907 股，平均價格為每股 26.42 美元，總計 50,382.94 美元。交易完成後，她直接擁有該公司80,495股股票，價值2,126,677.90美元。

CEO John M. Evans sold 60,000 shares on January 31st at an average price of $25.33 per share, totaling $1,519,800.00. After the sale, he directly owns 1,058,262 shares, valued at $26,805,776.46.

執行長 John M. Evans 於 1 月 31 日出售了 60,000 股，平均價格為每股 25.33 美元，總計 1,519,800.00 美元。出售後，他直接擁有1,058,262股，價值26,805,776.46美元。

In addition to these insider sales, insider Christine Bellon sold another 1,907 shares on January 3rd at the same price of $26.42 per share, bringing her total holdings to 80,495 shares worth $2,126,677.90.

除了這些內部人士出售之外，內部人士克里斯蒂娜·貝隆(Christine Bellon) 於1 月3 日以每股26.42 美元的相同價格另外出售了1,907 股，使她的總持股量達到80,495 股，價值2,126,677.90 美元。

Over the past 90 days, insiders have sold a total of 63,472 shares of Beam Therapeutics stock, valued at $1,618,322. Insiders currently own 4.40% of the company's shares.

在過去 90 天裡，內部人士總共出售了 63,472 股 Beam Therapeutics 股票，價值 1,618,322 美元。內部人士目前持有該公司4.40%的股份。

Stock Performance and Financial Results

股票表現和財務業績

Beam Therapeutics' stock has witnessed fluctuations in recent times. On Thursday, BEAM traded down $0.92 to close at $33.04. The stock has a 12-month low of $16.95 and a 12-month high of $49.50, with an average daily trading volume of 1,378,971 shares.

Beam Therapeutics 的股票近期出現波動。週四，BEAM 下跌 0.92 美元，收在 33.04 美元。該股12個月最低點為16.95美元，12個月最高點為49.50美元，每日平均成交量為1,378,971股。

The company's financial performance has been promising. On February 27th, Beam Therapeutics announced its fourth-quarter earnings, reporting earnings per share (EPS) of $1.73, exceeding analysts' consensus estimates by $2.42. Revenue for the quarter reached $316.20 million, significantly surpassing analyst expectations of $34.16 million.

該公司的財務表現一直充滿希望。 2 月 27 日，Beam Therapeutics 公佈第四季財報，每股盈餘 (EPS) 為 1.73 美元，比分析師普遍預期高出 2.42 美元。該季度營收達到 3.162 億美元，大幅超出分析師預期的 3,416 萬美元。

For the full year, equities analysts anticipate that Beam Therapeutics will post a loss per share of $5.50.

股票分析師預計 Beam Therapeutics 全年每股虧損 5.50 美元。

Analyst Opinions and Recommendations

分析師意見與建議

Beam Therapeutics has attracted the attention of numerous analysts. Jefferies Financial Group maintained a "hold" rating but lowered its price target from $75.00 to $30.00. Bank of America downgraded the stock from "buy" to "neutral" and set a price objective of $35.00.

Beam Therapeutics 吸引了許多分析師的注意。 Jefferies Financial Group 維持「持有」評級，但將目標價從 75.00 美元下調至 30.00 美元。美國銀行將該股評級從“買入”下調至“中性”，並將目標價設定為 35.00 美元。

TheStreet upgraded BEAM from a "d" rating to a "c-" rating. Barclays raised its price target from $26.00 to $42.00 and gave the company an "equal weight" rating. JPMorgan Chase & Co. upgraded the stock from "neutral" to "overweight" and increased its target price from $38.00 to $40.00.

TheStreet 將 BEAM 從“d”評級升級為“c-”評級。巴克萊將目標價從 26.00 美元上調至 42.00 美元，並給予該公司「同等權重」評級。摩根大通將該股評級從“中性”上調至“增持”，並將目標價從 38.00 美元上調至 40.00 美元。

Currently, eight analysts have assigned Beam Therapeutics a "hold" rating, while five have given it a "buy" rating. The consensus target price among analysts is $41.00, suggesting a potential upside for investors.

目前，有八位分析師給予 Beam Therapeutics 「持有」評級，五位分析師給予其「買入」評級。分析師一致的目標價為 41.00 美元，這表明投資者有潛在的上漲空間。

About Beam Therapeutics

關於光束療法

Beam Therapeutics is a biotechnology company developing precision genetic medicines for serious diseases. The company's pipeline includes BEAM-101 for sickle cell disease or beta-thalassemia; BEAM-201 for refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301 and BEAM-302 for glycogen storage disease 1a and severe alpha-1 antitrypsin deficiency, respectively.

Beam Therapeutics 是一家生技公司，致力於開發針對嚴重疾病的精準基因藥物。該公司的產品線包括治療鐮狀細胞疾病或β地中海貧血的BEAM-101； BEAM-201治療難治性T細胞急性淋巴性白血病/T細胞淋巴母細胞淋巴瘤； BEAM-301 和 BEAM-302 分別用於治療肝醣累積病 1a 和嚴重 α-1 抗胰蛋白酶缺乏症。